Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Lenalidomide for myelodysplastic syndromes: finally, hope not hype

Nature Clinical Practice Oncology volume 2, pages 390–391 (2005)Cite this article

boxed-textList A et al. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352: 549–557

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Raza A et al. (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98: 958–965

    Article  CAS  Google Scholar 

  2. Le Beau MM et al. (1986) Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 4: 325–345

    Article  CAS  Google Scholar 

  3. Liu JJ et al. (2003) Erythroid gene suppression by NF-kappa B. J Biol Chem 278: 19534–19540

    Article  CAS  Google Scholar 

  4. Corral LG et al. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163: 380–386

    CAS  PubMed  Google Scholar 

  5. Raza A et al. (2004) Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45: 2099–2104

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. MDS Center,

    Azra Raza & Naomi Galili

  2. Molecular Genetics Laboratory at the MDS Center, at the University of Massachusetts, Worcester, MA, USA

    Azra Raza & Naomi Galili

Authors
  1. Azra Raza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naomi Galili
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Azra Raza.

Ethics declarations

Competing interests

A Raza is on the speakers' bureau, receives free drug/research grants and has been a consultant for Celgene Corp.

Glossary

INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)

A classification system to determine the severity of myelodysplastic syndromes, the chances of a patient's survival and the probability that disease progression to acute myeloid leukemia will occur

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raza, A., Galili, N. Lenalidomide for myelodysplastic syndromes: finally, hope not hype. Nat Rev Clin Oncol 2, 390–391 (2005). https://doi.org/10.1038/ncponc0244

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0244

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing